Loading...
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
Fuggle, Nicholas Al-Daghri, Nasser Bock, Olivier Branco, Jaime Bruyère, Olivier Casado, Enrique Cavalier, Etienne Cortet, Bernard de Wit, Maarten Giusti, Andrea
Fuggle, Nicholas
Al-Daghri, Nasser
Bock, Olivier
Branco, Jaime
Bruyère, Olivier
Casado, Enrique
Cavalier, Etienne
Cortet, Bernard
de Wit, Maarten
Giusti, Andrea
Author
Fuggle, Nicholas
Al-Daghri, Nasser
Bock, Olivier
Branco, Jaime
Bruyère, Olivier
Casado, Enrique
Cavalier, Etienne
Cortet, Bernard
de Wit, Maarten
Giusti, Andrea
Halbout, Phillippe
Harvey, Nicholas C.
Hiligsmann, Mickaël
Kaufman, Jean‑Marc
Kurth, Andreas
Maggi, Stefania
Matijevic, Radmila
Minisola, Salvatore
Palacios, Santiago
Radermecker, Régis
Thomasius, Friederike
Tuzun, Sansin
Veronese, Nicola
Kanis, John A.
Reginster, Jean-Yves
Rizzoli, René
Cooper, Cyrus
Al-Daghri, Nasser
Bock, Olivier
Branco, Jaime
Bruyère, Olivier
Casado, Enrique
Cavalier, Etienne
Cortet, Bernard
de Wit, Maarten
Giusti, Andrea
Halbout, Phillippe
Harvey, Nicholas C.
Hiligsmann, Mickaël
Kaufman, Jean‑Marc
Kurth, Andreas
Maggi, Stefania
Matijevic, Radmila
Minisola, Salvatore
Palacios, Santiago
Radermecker, Régis
Thomasius, Friederike
Tuzun, Sansin
Veronese, Nicola
Kanis, John A.
Reginster, Jean-Yves
Rizzoli, René
Cooper, Cyrus
Abstract
Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk–benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes.
Keywords
osteoporosis, bisphosphonates, fragility fracture, therapy, risedronate, alendronate
Date
2022
Type
Journal article
Journal
Aging Clinical and Experimental Research
Book
Volume
34
Issue
11
Page Range
2625-2634
Article Number
ACU Department
Mary MacKillop Institute for Health Research
Faculty of Health Sciences
Faculty of Health Sciences
Collections
Relation URI
Source URL
Event URL
Open Access Status
License
CC BY 4.0
File Access
Open